AIRLINK 80.60 Increased By ▲ 1.19 (1.5%)
BOP 5.26 Decreased By ▼ -0.07 (-1.31%)
CNERGY 4.52 Increased By ▲ 0.14 (3.2%)
DFML 34.50 Increased By ▲ 1.31 (3.95%)
DGKC 78.90 Increased By ▲ 2.03 (2.64%)
FCCL 20.85 Increased By ▲ 0.32 (1.56%)
FFBL 33.78 Increased By ▲ 2.38 (7.58%)
FFL 9.70 Decreased By ▼ -0.15 (-1.52%)
GGL 10.11 Decreased By ▼ -0.14 (-1.37%)
HBL 117.85 Decreased By ▼ -0.08 (-0.07%)
HUBC 137.80 Increased By ▲ 3.70 (2.76%)
HUMNL 7.05 Increased By ▲ 0.05 (0.71%)
KEL 4.59 Decreased By ▼ -0.08 (-1.71%)
KOSM 4.56 Decreased By ▼ -0.18 (-3.8%)
MLCF 37.80 Increased By ▲ 0.36 (0.96%)
OGDC 137.20 Increased By ▲ 0.50 (0.37%)
PAEL 22.80 Decreased By ▼ -0.35 (-1.51%)
PIAA 26.57 Increased By ▲ 0.02 (0.08%)
PIBTL 6.76 Decreased By ▼ -0.24 (-3.43%)
PPL 114.30 Increased By ▲ 0.55 (0.48%)
PRL 27.33 Decreased By ▼ -0.19 (-0.69%)
PTC 14.59 Decreased By ▼ -0.16 (-1.08%)
SEARL 57.00 Decreased By ▼ -0.20 (-0.35%)
SNGP 66.75 Decreased By ▼ -0.75 (-1.11%)
SSGC 11.00 Decreased By ▼ -0.09 (-0.81%)
TELE 9.11 Decreased By ▼ -0.12 (-1.3%)
TPLP 11.46 Decreased By ▼ -0.10 (-0.87%)
TRG 70.23 Decreased By ▼ -1.87 (-2.59%)
UNITY 25.20 Increased By ▲ 0.38 (1.53%)
WTL 1.33 Decreased By ▼ -0.07 (-5%)
BR100 7,626 Increased By 100.3 (1.33%)
BR30 24,814 Increased By 164.5 (0.67%)
KSE100 72,743 Increased By 771.4 (1.07%)
KSE30 24,034 Increased By 284.8 (1.2%)
World

India's COVID-19 vaccination drive hits bump due to app glitch

  • India was aiming to vaccinate more than 300,000 people on Saturday, but only 191,181 people were inoculated on the first day.
Published January 17, 2021

SATARA/BHUBANESWAR: India's COVID-19 vaccination drive was still facing some delays on Sunday after it hit a bump on the first day due to glitches in an app used to coordinate the campaign, according to officials in some states.

Prime Minister Narendra Modi launched on Saturday what his government has described as the "world's largest vaccination programme". It aims to vaccinate around 300 million people to curb the pandemic in India, which has reported the second highest number of coronavirus cases after the United States.

India was aiming to vaccinate more than 300,000 people on Saturday, but only 191,181 people were inoculated on the first day, official data shows.

Many health workers, who were due to receive a vaccine on Saturday, did not get the message via an app developed by the government called Co-Win, officials in at least four states said. Officials in at least one state said the issues had still not been resolved on Sunday.

Co-Win is supposed to alert healthcare workers, who are first in line to get shots. It also allows officials to monitor and manage the entire programme.

"We were planning to vaccinate 28,500 people on Saturday but could do only 18,328 because of glitches in the Co-Win app," a senior official at the health department of the western state of Maharashtra told Reuters on condition on anonymity.

Maharashtra, home to the financial hub of Mumbai, has been the Indian state hit hardest by COVID-19.

In the eastern states of Odisha and West Bengal, officials said they were forced to use printouts on Saturday due to issues with the app.

"We also went with our plan B and contacted people to be vaccinated directly offline," Bijay Kumar Mohapatra, director, Health Services, Odisha, told Reuters in the state capital Bhubaneswar.

The Indian government did not respond to a request for comment on Sunday.

"The system performance and speed was improved and is being further optimised," Manohar Agnani, a senior health ministry official, said on Saturday.

The eastern state of West Bengal was still encountering glitches on Sunday.

"The problem is yet to be fixed and we are facing serious impediments," said Dr. Ajoy Chakraborty, director of West Bengal health services.

Officials in other states could not be reached for comment on Sunday.

India is currently using Britain's Oxford University/AstraZeneca vaccine, which is also being produced in India, and a government-backed vaccine developed by India's Bharat Biotech.

However, approval of Bharat Biotech's COVAXIN has been criticised by health experts and opposition lawmakers due to a lack of efficacy data, which the manufacturer is still conducting.

Comments

Comments are closed.